| $385M | ||
| $350M | ||
| $215M | ||
| $82M | ||
| $76M | ||
| $62M |
Buys | $0 | 0 | 0 |
Sells | $1,200,223 | 11 | 100 |
| Farmer Michele | See Remarks | 0 | $0 | 4 | $89,566 | $-89,566 |
| Van Oene Mark | See Remarks | 0 | $0 | 4 | $339,347 | $-339,347 |
| HENRY CHRISTIAN O | See Remarks | 0 | $0 | 3 | $771,310 | $-771,310 |
Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing systems to resolve genetically complex problems. The company provides PacBio's Systems, which conduct, monitor, and analyse biochemical sequencing reactions; consumable products, including single molecule real-time (SMRT) cells; and various reagent kits designed for specific workflow, such as template preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases. It also offers binding kits, such as modified DNA polymerase used to bind SMRTbell libraries to the polymerase in preparation for sequencing; and sequencing kits comprise reagents required for on-instrument, real-time sequencing, including the phospholinked nucleotides. The company serves research institutions; commercial laboratories; genome centers; public health labs, hospitals and clinical research institutes, contract research organizations, and academic institutions; pharmaceutical companies; and agricultural companies. It markets its products through a direct sales force in North America and Europe, as well as through distribution partners in Asia, Europe, the Middle East, Africa, and Latin America. Pacific Biosciences of California, Inc. has a development and commercialization agreement with Invitae Corporation. The company was formerly known as Nanofluidics, Inc. and changed its name to Pacific Biosciences of California, Inc. in 2005. Pacific Biosciences of California, Inc. was incorporated in 2000 and is headquartered in Menlo Park, California.
Over the last 12 months, insiders at Pacific Biosciences of California, Inc. have bought $0 and sold $1.2M worth of Pacific Biosciences of California, Inc. stock.
On average, over the past 5 years, insiders at Pacific Biosciences of California, Inc. have bought $176,160 and sold $2.39M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 40,000 shares for transaction amount of $176,160 was made by Meline David W (director) on 2024‑03‑06.
| 2026-03-03 | Sale | HENRY CHRISTIAN O | See Remarks | 12,497 0.0039% | $1.51 | $18,920 | +2.32% | |
| 2026-03-03 | Sale | Van Oene Mark | See Remarks | 6,504 0.002% | $1.51 | $9,847 | +2.32% | |
| 2026-03-03 | Sale | Farmer Michele | See Remarks | 2,979 0.0009% | $1.51 | $4,510 | +2.32% | |
| 2026-02-18 | Sale | HENRY CHRISTIAN O | See Remarks | 140,874 0.0466% | $1.63 | $229,484 | -0.31% | |
| 2026-02-18 | Sale | Van Oene Mark | See Remarks | 55,107 0.0182% | $1.63 | $89,769 | -0.31% | |
| 2026-02-18 | Sale | Farmer Michele | See Remarks | 14,952 0.0049% | $1.63 | $24,357 | -0.31% | |
| 2026-02-17 | Sale | HENRY CHRISTIAN O | See Remarks | 331,793 0.1096% | $1.58 | $522,906 | +4.24% | |
| 2026-02-17 | Sale | Van Oene Mark | See Remarks | 129,790 0.0429% | $1.58 | $204,549 | +4.24% | |
| 2026-02-17 | Sale | Farmer Michele | See Remarks | 35,215 0.0116% | $1.58 | $55,499 | +4.24% | |
| 2025-08-18 | Sale | Van Oene Mark | See Remarks | 26,836 0.0088% | $1.31 | $35,182 | +32.71% | |
| 2025-05-19 | Sale | Farmer Michele | See Remarks | 5,195 0.0017% | $1.00 | $5,200 | +52.70% | |
| 2025-03-03 | Sale | HENRY CHRISTIAN O | See Remarks | 12,497 0.0049% | $1.41 | $17,583 | +5.30% | |
| 2025-03-03 | Sale | Van Oene Mark | See Remarks | 6,486 0.0025% | $1.41 | $9,126 | +5.30% | |
| 2025-03-03 | Sale | Farmer Michele | See Remarks | 2,973 0.0012% | $1.41 | $4,183 | +5.30% | |
| 2025-02-18 | Sale | HENRY CHRISTIAN O | See Remarks | 259,909 0.0963% | $1.88 | $488,109 | -25.67% | |
| 2025-02-18 | Sale | Van Oene Mark | See Remarks | 100,773 0.0374% | $1.88 | $189,252 | -25.67% | |
| 2025-02-18 | Sale | Farmer Michele | See Remarks | 24,349 0.009% | $1.88 | $45,727 | -25.67% | |
| 2025-01-10 | Sale | Van Oene Mark | See Remarks | 34,405 0.0121% | $2.03 | $69,980 | -34.29% | |
| 2024-09-30 | Sale | Kim Susan G. | See Remarks | 19,782 0.0072% | $1.72 | $34,065 | -18.82% | |
| 2024-09-16 | Sale | HENRY CHRISTIAN O | See Remarks | 98,907 0.0343% | $1.75 | $172,692 | -21.62% |
| HENRY CHRISTIAN O | See Remarks | 3581813 1.186% | $4.94M | 0 | 18 | |
| Van Oene Mark | See Remarks | 2243634 0.7429% | $3.1M | 0 | 15 | |
| Farmer Michele | See Remarks | 305948 0.1013% | $422,208.24 | 0 | 12 | |
| Turner Stephen W | VP & Chief Technology Officer | 1025163 0.3395% | $1.41M | 0 | 3 | |
| BARNES SUSAN K | EVP, CFO and PAO | 874812 0.2897% | $1.21M | 0 | 2 | |
| Eidel Jeff | See Remarks | 869730 0.288% | $1.2M | 0 | 3 | |
| Hunkapiller Michael | director | 848405 0.2809% | $1.17M | 20 | 28 | +56.73% |
| Kim Susan G. | See Remarks | 695654 0.2304% | $960,002.52 | 0 | 10 | |
| Phillips James Michael | SVP, Research & Development | 249220 0.0825% | $343,923.60 | 8 | 7 | +10.38% |
| Fromen Peter | Chief Commercial Officer | 140280 0.0465% | $193,586.40 | 0 | 1 | |
| Schaefer Eric | Chief Accounting Officer | 88474 0.0293% | $122,094.12 | 0 | 1 | |
| CORCORAN KEVIN P | SVP, Market Development | 40455 0.0134% | $55,827.90 | 3 | 0 | <0.0001% |
| Meline David W | director | 40000 0.0132% | $55,200.00 | 1 | 0 | <0.0001% |
| ORDONEZ KATHY | director | 18595 0.0062% | $25,661.10 | 0 | 4 | |
| Ericson William W. | director | 18795 0.0062% | $25,937.10 | 12 | 2 | +17.15% |
| Dow Brian B | VP and PAO | 18119 0.006% | $25,004.22 | 1 | 0 | <0.0001% |
| LIVINGSTON RANDALL S | director | 0 0% | $0 | 0 | 1 | |
| Shapiro Lucy | director | 0 0% | $0 | 0 | 1 | |
| Botstein David | director | 0 0% | $0 | 0 | 1 |
| Increased Positions | 115 | +50.22% | 43M | +23.3% |
| Decreased Positions | 88 | -38.43% | 23M | -12.41% |
| New Positions | 43 | New | 16M | New |
| Sold Out Positions | 37 | Sold Out | 18M | Sold Out |
| Total Postitions | 256 | +11.79% | 205M | +10.89% |
| Ark Investment Management Llc | $56,900.00 | 10.24% | 30.92M | -5M | -14.8% | 2025-09-30 |
| Blackrock, Inc. | $41,760.00 | 7.52% | 22.7M | +42,878 | +0.19% | 2025-09-30 |
| Softbank Group Corp. | $37,631.00 | 6.77% | 20.45M | 0 | 0% | 2025-09-30 |
| Vanguard Group Inc | $30,139.00 | 5.42% | 16.38M | +362,797 | +2.27% | 2025-09-30 |
| Edmond De Rothschild Holding S.A. | $19,642.00 | 3.54% | 10.68M | -3M | -20.13% | 2025-09-30 |
| Sumitomo Mitsui Trust Group, Inc. | $15,967.00 | 2.87% | 8.68M | -540,897 | -5.87% | 2025-09-30 |
| Amova Asset Management Americas, Inc. | $15,967.00 | 2.87% | 8.68M | -540,897 | -5.87% | 2025-09-30 |
| Geode Capital Management, Llc | $12,708.00 | 2.29% | 6.91M | +187,776 | +2.79% | 2025-09-30 |
| State Street Corp | $10,874.00 | 1.96% | 5.91M | +155,061 | +2.69% | 2025-09-30 |
| Madrone Advisors, Llc | $9,156.00 | 1.65% | 4.98M | -12M | -70.31% | 2025-09-30 |